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ABSTRACT
The cyclin D1 gene encodes the regulatory subunit of a holoenzyme that drives 
cell autonomous cell cycle progression and proliferation. Herein we show cyclin D1 
abundance is increased >30-fold in the stromal fibroblasts of patients with invasive 
breast cancer, associated with poor outcome. Cyclin D1 transformed hTERT human 
fibroblast to a cancer-associated fibroblast phenotype. Stromal fibroblast expression 
of cyclin D1 (cyclin D1Stroma) in vivo, enhanced breast epithelial cancer tumor growth, 
restrained apoptosis, and increased autophagy. Cyclin D1Stroma had profound effects on 
the breast tumor microenvironment increasing the recruitment of F4/80+ and CD11b+ 
macrophages and increasing angiogenesis. Cyclin D1Stroma induced secretion of factors 
that promoted expansion of stem cells (breast stem-like cells, embryonic stem cells 
and bone marrow derived stem cells). Cyclin D1Stroma resulted in increased secretion 
of proinflammatory cytokines (CCL2, CCL7, CCL11, CXCL1, CXCL5, CXCL9, CXCL12), 
CSF (CSF1, GM-CSF1) and osteopontin (OPN) (30-fold). OPN was induced by cyclin 
D1 in fibroblasts, breast epithelial cells and in the murine transgenic mammary gland 
and OPN was sufficient to induce stem cell expansion. These results demonstrate that 
cyclin D1Stroma drives tumor microenvironment heterocellular signaling, promoting 
several key hallmarks of cancer.
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INTRODUCTION
The cyclin D1 gene encodes the regulatory subunit 
of a holoenzyme that phosphorylates and inactivates the 
retinoblastoma (pRb) protein, promoting G1/S phase 
cell cycle entry. Cyclin D1 enhances breast cancer 
cellular proliferation in vivo and endogenous cyclin D1 
maintains estradiol-mediated mammary epithelial cell 
gene expression in vivo [1]. The abundance of cyclin D1 
is rate limiting in the growth of tumors in vivo, including 
ErbB2-induced breast cancer [2, 3] and gastrointestinal 
tumorigenesis [4]. In addition to canonical signaling 
governing the G1/S cell-cycle transition, cyclin D1 also 
participates in non canonical cell autonomous functions. 
Thus cyclin D1 promotes cellular migration [5] and DNA 
repair [6], governs the expression of specific miRNAs 
and determines the processing of miRNA through the 
induction of Dicer [7]. The ability of cyclin D1 to govern 
gene transcription correlates with the recruitment of 
cyclin D1 and cointegrator enzyme complexes into the 
promoter regulatory region of target genes in the context 
of chromatin [8, 9]. 
An historical view has focused on oncogenic 
signaling within tumor cells that drive the hallmarks of 
cancer [10]. However, solid tumors consist of both tumor 
cells and stromal cells. Modification of fibroblasts in the 
stroma immediately adjacent to transformed epithelial 
cells has been documented in several tumor systems 
[11-15]. Cancer-associated fibroblasts (CAFs) are a 
preponderant stromal population in many tumor types 
[16]. CAFs originate from different cell populations 
including bone-marrow mesenchymal stem cells [17], 
resident fibroblasts [18], cancer cells (following epithelial 
to mesenchymal transition (EMT)) or endothelial cells [19, 
20]. The growth characteristics of breast cancer-associated 
fibroblasts are different from those of fibroblasts associated 
with normal breast epithelial cells [21]. CAFs associated 
with invasive breast carcinoma cells convey abnormal 
migratory behavior in vitro [22] and altered expression 
of growth factors such as platelet-derived growth factor, 
insulin-like growth factors I and II, transforming growth 
factor-β1, hepatocyte growth factor/epithelial scatter 
factor, and keratinocyte growth factor [21, 23-27] and 
increased expression of inflammatory genes [28].
Studies of fibroblasts in the vicinity of the 
malignant lesion support a role for stromal cells in 
tumorigenesis [29, 30]. In these circumstances genetic 
changes in the epithelial cell compartment are considered 
to be the independent drivers of the tumor inflammatory 
microenvironment. Evidence suggests that oncogenic and 
collaborative oncogenic signals within tumor epithelial 
cells recruit inflammatory cells which alter stromal 
fibroblasts to become cancer-associated fibroblasts 
(CAFs). Tumor cell derived inflammatory cytokines and 
growth factors including colony stimulating factor (CSF-
1), GM-CSF, CCL2 and other factors which participate in 
tumor progression [31]. 
Currently, relatively little evidence supports an 
alternate model in which changes in the expression 
of a target gene within the CAFs drive tumorigenesis. 
Furthermore, the molecular genetic drivers governing the 
CAF phenotype are not well understood. It is however 
known that intratumoral hypoxia, which down regulates 
caveolin-1 via lysosomal degradation [32-35], augments 
the CAF phenotype [34]. Herein we show the expression 
of the cyclin D1 gene is increased in human breast cancer 
stroma. We show that increased expression of cyclin 
D1 in stromal fibroblasts can transform it to a cancer-
associated fibroblast phenotype and that stromal cyclin 
D1 is sufficient to augment breast tumor epithelial cell 
growth in mice. Analysis of heterotypic signals induced 
by stromal cyclin D1 identified activation of heterocellular 
signaling that promoted tumor inflammation, angiogenesis 
and stem cell expansion.
RESULTS
Cyclin D1 expression is increased in the stroma 
of human breast cancer associated with poor 
prognosis
In view of the finding that the cyclin D1 gene 
encodes the regulatory subunit of the holoenzyme that 
phosphorylates pRB, and RB phosphorylation is increased 
in human breast cancer-associated fibroblasts [34], we 
determined the abundance of cyclin D1 in the stroma 
of human breast cancers. The mRNA for cyclin D1 was 
increased approximately 32-fold in breast cancer (Figure 
1A, 1B).
A cohort of 914 breast cancer specimens with 
available clinical outcome was stained for stromal cyclin 
D1 using immunofluorescence-immunohistochemistry. 
Tissue Studio (Definiens) quantitative analysis was 
performed on high-resolution digital images obtained 
using the ScanScope FL line scanner (Leica Biosystems) 
to determine levels of cyclin D1 expression specifically 
within the stroma of cancer specimens. A majority of the 
cyclin D1-positive cells in breast cancer stroma display 
a fibroblastoid phenotype with their characteristic highly 
elongated nuclei (Supplementary Figure 1A). Some 
stromal cell nuclei appear round and may represent other 
cell types but could also be fibroblastoid cells sectioned 
transversely. For immunostaining of cyclin D1 in human 
breast cancer specimens we have used clinical grade 
DAKO 3642 rabbit monoclonal antibody specific for 
the 36 kDa human cyclin D1. The antibody has been 
validated for formalin-fixed paraffin-embedded tissue 
and is widely used. As expected, the majority of cyclin 
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Figure 1: Cyclin D1 is increased in the stroma of human breast cancer associated with poor outcome. A.. The relative 
abundance of cyclin D1 in either the normal breast (N = 6) or breast cancer stroma (N = 53) was quantitated as mean ± SEM and 
shown as either Log2 or B. relative mRNA abundance. C. Kaplan-Meier plot indicating unfavorable prognosis in breast cancer patients 
with high cyclin D1 in stromal cells. Quantitative immunofluorescence and data-driven dichotomization of nuclear cyclin D1 levels in 
breast cancer stromal cells is associated with increased risk of disease recurrence (N = 914, p = 0.03). D. Venn diagram of GO terms, 
or E. gene expression comparing cancer-associated fibroblast (CAF) genes (breast cancer-associated fibroblasts compared with normal 
mammary gland fibroblasts [34] and cyclin D1 induced genes in fibroblasts [62]). F. Relative number of fibroblasts or G. breast cancer cells 
determined in co-culture of hTERT fibroblasts (control) or hTERT fibroblasts expressing cyclin D1 (cyclin D1stroma) co-incubated with the 
breast cancer cell line, MDA-MB-231 (N = 7 for cyclin D1stroma and N = 12 for control at time 72 hour. N = 2 for all of other time points). 
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D1 staining is in the cell nuclei (Supplementary Figure 
1A). Data-driven cutpoint analysis using X-tile software 
[36] identified a sub-population of patients with the 
highest levels of nuclear cyclin D1 within the stromal 
cell compartment (Supplementary Figure 1A) to be at a 
significantly increased risk of breast cancer recurrence 
(Cox Regression Hazard Ratio = 1.76 (CI: 1.20-2.57), 
p = 0.004) (Figure 1C). Furthermore the stromal cyclin 
D1 levels in the tumor were significantly greater than the 
adjacent normal stromal cyclin D1 in the same patients 
(Supplementary Figure 1B). Cancer-associated fibroblasts 
(CAFs) from human breast cancers compared with normal 
mammary fibroblasts isolated from patients are enriched 
for gene expression associated with cellular proliferation 
and pRb/E2F target genes [34]. A comparison of the GO 
terms evidenced a 64% (9/14) overlap of functional terms 
induced by cyclin D1 and induced in CAFs compared with 
normal mammary fibroblasts (Figure 1D). A comparison 
of cyclin D1-regulated genes in fibroblasts with gene 
expression induced in CAFs demonstrated 20/126 (16%) 
of genes were concordant (Figure 1E). 
When co-cultured with breast cancer cells, 
hTERT immotalizd human fibroblasts can acquire a 
cancer-associated fibroblast phenotype [37]. In order 
to determine the functional consequence of cyclin D1 
expression in the stromal fibroblasts, cyclin D1 was 
stably integrated into hTERT fibroblasts. Western blot 
analysis of the hTERT cells overexpressing cyclin D1 
(cyclin D1Stroma) demonstrated a 2-fold increase in cyclin 
D1 abundance, which is within the physiological range 
of changes in cyclin D1 abundance (Figure 1G). Breast 
cancer cellular growth, and co-culture experiments were 
conducted as previously described [38]. MDA-MB-231 
cells were grown with hTERT fibroblasts expressing 
cyclin D1 (cyclin D1Stroma) or its control GFP vector 
(controlStroma). The proliferation of hTERT fibroblasts 
with overexpression of cyclin D1 was increased 2-fold 
(p-value = 0.011), consistent with the known role for 
cyclin D1 to promote cellular proliferation (Figure 1F). 
The proliferation of MDA-MB-231 cells was increased 
approximately 65% at 72 hrs by cyclin D1Stroma suggesting 
stromal cyclin D1 participates in heterocellular signals to 
the breast cancer cells (p-value = 0.004) (Figure 1G). 
Stromal cyclin D1 enhances tumor growth, 
proliferation and reduces apoptosis
In order to examine the functional significance of an 
increase in cyclin D1 expression in the tumor-associated 
fibroblasts, MDA-MB-231 cells were co-injected with 
hTERT fibroblasts expressing either cyclin D1 (cyclin 
D1Stroma) or control GFP vector (controlStroma). Tumors were 
visualized by the expression of the Luc2 gene (Figure 2A). 
Tumor weight was increased 40% (0.31 vs 0.22 grams 
(N = 6)), and tumor volume was increased 93% (351.5 
vs 182.3 µM x 1003 (N = 6)) (Figure 2B, 2C). Tumors 
were extirpated and analyzed for markers of proliferation, 
apoptosis and cancer-associated fibroblast differentiation 
(Figure 2D-2G). Ki-67, a marker of cellular proliferation, 
was increased 80% by cyclin D1Stroma in the breast cancer 
epithelial cells (11.7x104 vs 6.5x104, (N = 4)) (Figure 
2D). Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) staining as a measure of apoptosis 
was reduced 63% in the breast cancer epithelial cells by 
cyclin D1Stroma (21x104 vs 7.6x104 for N = 3) (Figure 2E). 
Induction of the cancer-associated fibroblast phenotype 
correlates with the expression of calponin and αSMA 
[37]. The cyclin D1Stroma breast tumors showed increased 
abundance of αSMA (Figure 2F, 2.6-fold, p = 0.018) and 
calponin (Figure 2G).
Stromal cyclin D1 enhances autophagy, features of 
the cancer-associated fibroblast, neoangiogenesis 
and tumor inflammation
The tumor stroma has the capacity to induce or 
restrain autophagy in the tumor epithelium [39]. In order to 
determine whether stromal cyclin D1 induced autophagy 
in the breast tumor we assessed known markers. LC3B, 
a marker of autophagy, was induced 40% in the breast 
cancer epithelial cells (12.4x104 vs 18.9x104 for N = 4) 
(Figure 3A). Breast cancer epithelial cell abundance of 
Beclin 1 (BCN1), a novel Bcl-2-interacting mammalian 
autophagy gene [40], was induced 50% by cyclin D1Stroma 
(Figure 3B). Chaperone-mediated autophagy (CMA) is 
a proteolytic system that degrades intracellular proteins 
in lysosomes. Lysosomal-associated membrane protein 1 
(LAMP-1) (also known as lysosome-associated membrane 
glycoprotein 1 and CD107a (Cluster of Differentiation 
107a)), is a marker for chaperone-mediated autophagy 
[41]. LAMP1 was induced 70% by cyclin D1Stroma (Figure 
3C, 2.1x105 vs 3.5x105, N = 4). Collectively these studies 
demonstrate that increased cyclin D1Stroma promotes breast 
cancer tumor growth, associated with the induction of 
cell proliferation, reduction in apoptosis and induction of 
autophagy in the breast cancer epithelial cell compartment.
As a surrogate for neoangiogenesis we measured the 
αvβ3 binding ECM protein von Willebrand Factor (vWF), 
which was increased 4-fold by cyclin D1Stroma (Figure 3D). 
Tumor-associated macrophages (TAMs) play a critical role 
in the proliferation, invasion, angiogenesis, and metastasis 
of human breast carcinomas [42, 43] and increased 
macrophage infiltration into tumors confers metastatic 
potential and poor prognosis in breast cancer [44]. We 
therefore analyzed the presence of F4/80+ macrophages, 
which were increased 2.5-fold by cyclin D1Stroma (Figure 
3E). The CD11b+ staining macrophages, which also 
contribute to breast cancer metastasis [45], were increased 
3.2-fold by cyclin D1Stroma (Figure 3F). 
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Figure 2: Stromal cyclin D1 expression increases breast tumor growth in mice. A. Mice were injected with either hTERT control 
(controlstroma) or hTERT-cyclin D1 (cyclin D1stroma), in equal number together with MDA-MB-231 cells (RFP) and the tumor size assessed 
with B. tumor weight and C. tumor volume shown as mean ± SEM for N = 6 separate animals in each group. D. Immunohistochemical 
analysis of the tumors for cell proliferation (Ki-67), E. apoptosis (TUNEL), F. α-SMA and G. calponin with quantitation shown as mean ± 
SEM for N = 6 separate animals in each group. 
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Figure 3: Cyclin D1stroma expression increases breast cancer inflammation. A. Immunohistochemical analysis of the tumors 
for A.-C. mitophagy/autophagy (LC3B, BECN-1, LAMP-1), D. angiogenesis (Von Willebrand Factor (VWF), E. F4/80+ macrophages, F. 
CD11b+ macrophages, with quantitation shown as mean ± SEM for N = 6 separate animals in each group. 
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Cyclin D1 conditioned medium produces pro-
inflammatory cytokines (CCL2, CCL7, CCL11, 
CXCL1, CXCL5, CXCL9, CXCL12), CSF (CSF, 
G-CSF) and osteopontin (OPN)
In order to determine the mechanism by which 
cyclin D1Stroma promoted MDA-MB-231 tumor 
inflammation and growth, we analyzed cyclin D1Stroma 
secreted factors, measuring growth factors, cytokines and 
receptors (Figure 4A). Chemokines have been grouped 
into four subfamilies (CXC, CC, CX3C and C) on the 
basis of a structural cysteine motif found near the amino 
terminus. Comparing cyclin D1Stroma and controlStroma 
demonstrated the induction of CCL8 (MCP2, 8-fold), 
CCL7 (MCP3 39-fold), CXCL5 (39-fold), GM-CSF (10-
fold), CXCL1 (9-fold), TNFα, and TNFβ (Figure 4B). In 
order to determine the role of endogenous cyclin D1 in 
maintaining production of secreted factors we compared 
cyclin D1-/- with cyclin D1+/+ MEFs. Endogenous cyclin 
Figure 4: Fibroblast cyclin D1 expression increases secretion of inflammatory cytokines. A. Soluble growth factor/cytokine/
receptor array of conditioned medium from hTERT-controlstroma or hTERT-cyclin D1stroma or C.-F., from cyclin D1+/+ or cyclin D1-/- MEFs. 
Data is shown as fold change.
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D1 maintained abundance of CCL11, GM-CSF, IGFBP-6, 
IL-3Rb, IL-5, XCL1 (lymphotactin), CCL2, SCF, SDF-1α, 
VCAM (Figure 4C, 4D) and osteopontin (OPN), (30-fold) 
(Figure 4E, 4F). Collectively these studies demonstrated 
that increased cyclin D1 in fibroblasts induces the 
abundance of proinflammatory cytokines and chemokines. 
Figure 5: Proteome analysis of cyclin D1 conditioned medium identifies inflammatory cytokines and dendritic cell 
maturation pathways. A. Venn diagram comparing the overlap of proteins in secretomes of hTERT-controlstroma and hTERT-cyclin 
D1stroma cells (n = 3 for each condition). B. Hierarchical clustering heat map of hTERT-controlstroma and hTERT-cyclin D1stroma secretomes 
based on LFQ intensities of identified proteins. C. Volcano plot of proteins identified in secretome analysis. Log2 ratios of LFQ intensities in 
hTERT-cyclin D1stroma vs. hTERT-controlstroma were plotted against negative log10 Student’s t-test p-values. Significantly changed proteins, 
defined as absolute fold-change > 2 and p < 0.05, are shown in blue. D. Canonical pathways (Ingenuity Pathway Analysis) associated with 
secretome changes in hTERT-cyclin D1stroma relative to hTERT-controlstroma are shown for a significance threshold of absolute Fold-change 
> 2.5 and Student’s t-test p < 0.05. Bars represent negative log10 Fisher’s exact test, right-tailed p-values for each canonical pathway. The 
ratio of proteins that significantly changed relative to the total identified proteins in this dataset for each pathway is listed above each bar.
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Cyclin D1 conditioned medium proteomic analysis 
identified cytokines and pathways governing 
macrophage and dendritic cell maturation
To evaluate the extent to which cyclin D1 
regulates the tumor microenvironment, we performed 
an unbiased global secretome analysis of conditioned 
media from cyclin D1Stroma and controlStroma hTERT cell 
lines by analyzing biological triplicates for each group 
(Supplementary Table 1). A total of 935 proteins were 
identified by two or more peptides (final protein FDR 
= 0.5%) with 924 proteins (98.8%) detected in both 
groups (Figure 5A). Protein levels in the secretomes 
were determined using label free quantitation. Biological 
replicates were highly similar, while abundance levels of 
many secreted proteins were different between the groups 
(Figure 5B). At a threshold of absolute fold-change greater 
than 2 and Student’s t-test p-value less than 0.05, 250 
proteins (27% of identified proteins) were significantly 
different between the groups (Figure 5C) with 174 proteins 
upregulated and 76 downregulated in the cyclin D1Stroma 
relative to controlStroma. Canonical pathways significantly 
associated with cyclin D1 were primarily associated 
with cytokines and immune response, including “IL-
6 Signaling,” “Interferon Signaling,” “Dendritic Cell 
Maturation,” “Activation of IRF by Cytosolic Pattern 
Recognition Receptors,” and “Th1 Pathway” (Figure 5D). 
IL-6 was among the most upregulated proteins in cyclin 
D1Stroma exhibiting a 7-fold increase (Supplementary Table 
1). These results are consistent with a primary role for 
cyclin D1-regulated secreted factors in determining tumor 
cytokine signaling and the immune response. While some 
cytokines, osteopontin, and other proteins assayed by 
targeted approaches (Figure 4) were not identified in the 
proteome analysis, these proteins were most likely present 
at very low abundance levels that were below the detection 
threshold of the proteomics method used here.
Cyclin D1 conditioned medium induces expansion 
of CD34 positive hematopoietic stem cells (HSCs) 
and differentiation of CD34 positive hematopoietic 
stem cells (HSCs) into dendritic cells
CD11b+ macrophages are thought to participate in 
the progression of breast tumorigenesis [46], therefore 
we sought to examine further the mechanism by which 
cyclin D1 in the stroma may promote the production of 
CD11b+ cells. Myeloid-derived suppressor cells (MDSC) 
are a heterogeneous population of cells which strongly 
inhibit anti-cancer immune responses and in the mouse 
are characterized by the expression of CD11b. Given the 
increase in CD11b in the cyclin D1Stroma, we examined 
the potential role of cyclin D1-induced fibroblast 
heterocellular signals in the expansion of a CD11b+ 
population using murine bone marrow derived cells. 
CD34 is a marker of hematopoietic stem cells (HSC) 
[47]. In order to examine the mechanisms governing the 
induction of the CD11b+ from the hematopoietic stem 
cells, the murine bone marrow cells were cultured with the 
supernatant from either cyclin D1-/- or cyclin D1+/+ MEFs 
(Figure 6A). We used the standard HSC protocol with 
Flt3L media for 9 days and analyzed CD34 expression by 
flow cytometry. The histogram representing the percentage 
of CD34+ cells demonstrated that cyclin D1 conditioned- 
supernatant increased the percentage of CD34+ cells from 
14% to 35% (Figure 6A). 
In order to examined further the mechanisms by 
which cyclin D1-mediated secreted factors increased the 
proportion of CD11b+ cells, we investigated the potential 
role of the pRB protein. Comparison was therefore made 
of the secreted signals derived from cyclin D1-/-, pRB-/- 
and cyclin D1/pRB-/- MEFs. Western blot demonstrated 
loss of the cognate protein in the MEFs (Supplementary 
Figure 2A), maintenance of cellular diameter and reduced 
proliferation rates in the cyclin D1-/- cells (Supplementary 
Figure 2B, 2C). The supernatant derived from similar 
numbers of MEFs of each genotype were then used in 
assays with the murine bone marrow (Supplementary 
Figure 3). The CD34+ population was reduced from 35% 
to 27% when incubated with cyclin D1+/+/pRB-/- media, 
however the cyclin D1-/-/pRB-/- media resulted in 23% 
CD34+ cells, which was greater than the proportion shown 
from the supernatant of cyclin D1-/- MEFs. Together these 
studies suggest that endogenous cyclin D1-mediated 
secreted factors are the primary driver to expand CD34+ 
cells. 
The increase in CD11b+ MDSC by media derived 
from cyclin D1+/+ vs cyclin D1-/- MEFs is consistent with 
a role for endogenous fibroblast cyclin D1 in producing 
secreted factors that promote stem cell expansion. 
Traditional stem cell assays were therefore conducted, 
quantitating the number of embryonic stem cell colonies to 
determine the possibility that cyclin D1-mediated secreted 
factors promote stem cells. The supernatant was incubated 
with murine ES cells, and colony number determined. 
The conditioned medium from cyclin D1 expressing cells 
induced both mES cell proliferation and colony number 
(Figure 6B-6E). 
Cyclin D1 induces the secretion and cleavage of 
osteopontin (OPN)
In our assessment of cyclin D1-mediated soluble 
factors, OPN was induced 30-fold (Figure 4F). Elevated 
levels of OPN correlate with poor prognosis in breast 
cancer [48]. OPN is a soluble pleiotropic cytokine that 
binds to integrin receptors, including α4β1, α9β1, and 
α9β4 expressed by leukocytes, to induce cell adhesion, 
migration, and survival in immune cells (neutrophils, 
macrophages, T cells, mast cells, and osteoclasts [49, 50]. 
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Figure 6: Cyclin D1 conditioned medium induces expansion of CD34 positive hematopoietic stem cells (HSCs) and 
promotes differentiation of CD34 positive hematopoietic stem cells (HSCs) into dendritic cells. A. The bone marrow cells 
were cultured in media derived from cyclin D1-/- or cyclin D1+/+ MEFs for 9 days and analyzed for CD34 expression by flow cytometry 
as described in Materials and Methods. Histogram represents the percentage of CD34+ cells. The gate was set based on unstained and/or 
isotype control for each sample. B.-C. The supernatant from cyclin D1-/- or cyclin D1+/+ MEFs were incubated with ES cells and assessed 
for proliferation or D.,E. colony number. Quantitation of ES cell colony number shown as mean ± SEM for N = 3.
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Because OPN has the capacity to recapitulate many of 
the cyclin D1-mediated stromal effects, further analysis 
was conducted of cyclin D1 and OPN using cultured 
cells and transgenic mice. Cyclin D1 reintroduction 
into cyclin D1-/- MEFs induced OPN abundance (Figure 
7A). OPN is cleaved into active forms by thrombin and 
matrix melloproteases to form a C terminal fragment that 
is chemotactic to macrophages [51-53]. A comparison of 
cyclin D1-/- and cyclin D1+/+ MEF showed an increased 
abundance of the OPN cleaved forms (Figure 7B). As 
cleavage is conducted by matrix metalloproteases (MMP-
3, MMP-7) [54], we assessed the abundance of MMP by 
Western blot. MMP-3 was induced 7-fold in the cyclin 
D1+/+ cells (Figure 7B). This finding is consistent with 
recent studies in which cyclin D1 was shown to induce 
MMP gene expression in the mammary gland in vivo 
[1]. OPN abundance was determined by ELISA in the 
cell culture media of both of cyclin D1+/+ and cyclin D1-/- 
MEFs. Cyclin D1 increased OPN secretion approximately 
6-fold (Figure 7C). In order to determine whether cyclin 
D1 induces OPN in vivo, two transgenic paradigms were 
deployed. The first in which the abundance of cyclin D1 
is induced through a tetracycline inducible operator in the 
mammary gland of transgenic mice [9] (Figure 7D). 14 
days after the induction of the cyclin D1 transgene in the 
mammary gland, immunohistochemical staining showed a 
6-fold induction of OPN by the cyclin D1WT (Figure 7E). 
In order to determine whether endogenous cyclin 
D1 maintained OPN abundance, we assessed transgenic 
mice in which the cyclin D1 gene could be excised in the 
adult mammary gland. The inducible cyclin D1 genetic 
deletion mice (ROSA26-Cre-ERT2-cyclin D1fl/fl) [55] were 
treated with tamoxifen for 5 days (Figure 7F), and after a 
subsequent 28 days immunohistochemistry was conducted 
for OPN. Mammary gland staining for OPN was reduced 
3-fold in the cyclin D1 genetic deletion mice (Figure 
7G). In order to determine whether OPN as sufficient to 
induce the ES cell expansion demonstrated with cyclin 
D1 conditioned medium, ES cells assays were conducted 
in the presence of OPN or control. ES cell number was 
induced 1.75-fold (Figure 7H, (N = 2, P 0.06).
DISCUSSION
The current studies demonstrate that cyclin D1 
mRNA abundance is increased 30-fold in the stroma of 
patients with breast cancer. A quantitative analysis of 
stromal cyclin D1 protein in 914 patients demonstrated 
that increased nuclear stromal fibroblast expression of 
cyclin D1 predicted poor outcome. Previous publications 
did not report the presence of cyclin D1 protein in breast 
cancer stroma but focused on reporting the more abundant 
of cyclin D1 in cancer epithelial cells. In part, this could 
be due to lower sensitivity of the DAB chromogen 
staining used by these older publications compared to 
our immunofluorescence based staining. In general, 
chromogen (brightfield) stains block light and is hypo-
luminescent and has a signal range of only one log. In 
contrast, fluorescent signals emit light and are hyper-
luminescent with a signal range of 2-2.5 logs. Consistent 
with the functional significance of the increased cyclin 
D1 in the stroma, several target proteins known to be 
repressed by cyclin D1 (NRF1, mTTFA), were reduced in 
the stroma (data not shown). 
Breast epithelial cell cyclin D1 protein 
overexpression is found in up to 50% of human breast 
cancers [56]. Increased cyclin D1 gene copy number 
is found in up to 20% of breast tumors suggesting 
that activation of cyclin D1 can occur via additional 
mechanisms, including transcriptional and post-
transcriptional dysregulation. Prior studies had assessed 
the prognostic significance of nuclear cyclin D1 
abundance in the breast cancer epithelial cell. These prior 
studies demonstrated that increased nuclear epithelial 
cell cyclin D1 abundance correlates with better prognosis 
[57]. In these studies cyclin D1 mRNA levels in the cyclin 
D1 “high group” were induced 1.8-fold [57]. Cyclin 
D1 amplification or overexpression however identified 
a subset of ERα+ breast cancers with worse prognosis 
[58], suggesting additional interactions modify cyclin 
D1 function. As cyclin D1 has been shown to promote 
cellular migration it will be of interest in future studies 
to determine whether stromal cyclin D1 correlates with 
increased tumor invasiveness. The current studies provide 
evidence for the independent prognostic significance of 
stromal cyclin D1 and suggest consideration be given to 
evaluation of cyclin D1 in the stroma of breast cancer 
when considering patient prognosis. 
We determined the functional significance of 
stromal cyclin D1 through co-injecting hTERT fibroblasts 
expressing cyclin D1 (cyclin D1Stroma) or control GFP 
vector (controlStroma). Cyclin D1Stroma enhanced breast 
tumor volume 93%, with a 2-fold increase in breast cancer 
epithelial cell proliferation and a 63% reduction in breast 
tumor epithelial cell apoptosis. The finding that stromal 
cyclin D1 increased tumor growth is consistent with 
previous findings, in which cyclin D1 was shown to be a 
marker of senescent stroma [59] and senescent stroma was 
shown to stimulate tumor growth [60]. 
In the current co-culture studies, cyclin D1Stroma 
increased cellular proliferation, consistent with 
heterocellular signaling driving breast cancer tumor 
growth. Many of the growth factors and chemokines 
induced by cyclin D1Stroma are capable of promoting breast 
cancer epithelial cell proliferation and reducing breast 
cancer epithelial apoptosis. It is likely that combinatorial 
interactions of the secreted signals participate in the 
growth phenotype. Cyclin D1Stroma increased breast cancer 
epithelial cell autophagy, increasing the abundance of 
BCN1 and LAMP1. Increased tumor epithelial cell 
autophagy is thought to participate in tumor cell metabolic 
heterogeneity by driving epithelial cell catabolism and 
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Figure 7: Cyclin D1 induces Osteopontin (OPN) abundance. A. Western blot analysis for OPN in cyclin D1-/- MEFs transduced 
with either control vector or a cyclin D1 expressing vector. β-actin is a loading control. B. Western blot analysis of either wild type or cyclin 
D1-/- MEFs for the abundance of OPN and its bioactive cleaved forms, MMP3 (cleavge enzyme for OPN) and β-actin loading control. C. 
ELISA of OPN in cell culture media of either wild type or cyclin D1-/- MEFs. The serum-free cell cuture media were collected after 48 
hours. D. Schematic representation of transgenic mice in which a cyclin D1 cDNA was induced in the mammary gland upon addition of 
doxycycline. E. Immunohistochemistry for OPN in the mammary gland of transgenic mice with quantitation of IHC shown as mean + 
SEM for N = 3 separate mice. F. Schematic representation of transgenic paradigm to delete cyclin D1 in mice using tamoxifen inducible 
Cre expression. G. Immunohistochemistry for OPN in the mammary gland of transgenic mice with quantitation of IHC shown as mean 
± SEM for N = 3 separate mice. H. Assay of OPN mediated induction of embryonic stem (ES) cells. Image of the plates in which ES cell 
assays were conducted using either vehicle or OPN, with representative colonies shown at high magnification (200x). Quantitation of ES 
cell colony number shown as mean ± SEM for N =  3.
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glycolysis [39]. The mammalian gene encoding Beclin1, 
a novel Bcl-2-interacting mammalian autophagy gene, 
can inhibit tumorigenesis and is expressed at decreased 
levels in human breast carcinoma. Cell surface expression 
of LAMP1 can serve as a ligand for selectins and help 
mediate cell-cell adhesion correlating with increased 
cancer invasiveness. The finding that the stromal cyclin D1 
increases breast cancer autophagy contrasts with the cell 
autonomous function of cyclin D1 in tissue mono culture, 
wherein cyclin D1 restrains epithelial cells and fibroblast 
autophagy via phosphorylation of LKB1[61]. Thus cyclin 
D1 conveys tissue compartment specific effects, with 
stromal fibroblast cyclin D1 increasing autophagy, and 
epithelial cell cyclin D1 restraining autophagy.
In the current studies, cyclin D1 expression in 
fibroblasts determined a gene expression profile that 
overlapped with the previously described expression 
pattern associated of cancer-associated fibroblasts [34, 
62]. Of the 126 CAF-induced genes, 20 were also induced 
by cyclin D1. Of the 14 functional terms induced in 
CAFs, 9 functional terms were also induced by cyclin 
D1. Cyclin D1Stroma induced an inflammatory infiltration 
in the breast cancers with increased infiltration of CD11b+ 
macrophages. In mice, MDSCs are defined as being 
CD11b+ and Gr-1+. Canonical pathways significantly 
associated with cyclin D1 mediated secreted proteins 
were associated with “Dendritic Cell Maturation,” and 
cyclin D1 conditioned medium induced expansion of 
CD34 positive hematopoietic stem cells (HSCs) and 
differentiation of CD34 positive hematopoietic stem 
cells (HSCs) into dendritic cells. The current studies are 
consistent with a role for cyclin D1Stroma, in the induction 
of stem cells. Cyclin D1-mediated heterotypic factors 
increased the number of bone marrow derived stem cells 
(BMDSC) and increased embryonic stem cell (ESC) 
colonies 3-fold. We demonstrated that full length OPN 
enhanced the number of ES colonies approximately 
2-fold. Several cyclin D1-mediated secreted factors 
have the capacity to differentiate MDSC, including 
granulocyte macrophage-colony stimulating factor (GM-
CSF), macrophage-colony stimulating factor (M-CSF), 
and stem cell factor (SCF) [63, 64]. Cyclin D1 induced 
GM-CSF 1.75-fold and SCF 1.5-fold. We identified cyclin 
D1 at the regulatory region of the Csf1 gene in ChIP-seq 
(Supplementary Figure 4). As myeloid-derived suppressor 
cells (MDSCs) accumulate in tumors during malignant 
progression and in ex vivo CTL assays can suppress T cell 
responses [65] and block DC maturation at the invasive 
edge of tumors [65], the current studies suggest a novel 
mechanism by which stromal cyclin D1 may augment 
tumor progression.
What might be the functional significance of 
the cyclin D1-stroma–mediated induction of F4/80+ 
macrophages ? Monocytes and/or macrophages promote 
the extravasation, survival, and persistent growth of 
metastatic cells [66]. The role of M1 vs M2 macrophages, 
and markers used to define these populations remains 
controversial. However iNOS is produced by 
macrophages, and increased stromal iNOS correlated with 
mammary tumor progression [67]. In the current studies 
increased iNOS staining of macrophages was observed 
in the cyclin D1 stroma tumors in vivo (data not shown), 
consistent with a protumorigenic role of the cyclin D1 
stromal-augmented tumor inflammation.
Increased expression of fibroblast cyclin D1 induced 
the abundance of inflammatory chemokines/cytokines in 
fibroblasts, that are known to promote tumorigenesis. 
Cyclin D1 conditioned medium produced pro-
inflammatory cytokines (CCL2, CCL7, CCL11, CXCL1, 
CXCL5, CXCL9, CXCL12), CSF (CSF, G-CSF) and 
osteopontin (OPN). Several of the individual components 
of the secretome, induced by cyclin D1Stroma, were 
previously described as tumor stroma secreted factors. 
In addition to cytokines/chemokines, proteomic analysis 
showed increased secretion of 176 proteins in response 
to cyclin D1 expression, that correlated with functional 
pathways including “IL-6 signaling”, “interferon 
signaling”, and “dendritic cell maturation”. Endogenous 
cyclin D1 maintained abundance of stromal cell-derived 
factor 1 (SDF-1α), also called CXCL12, which plays 
a central role in the promotion of tumor growth and 
angiogenesis. SDF-1α stimulates carcinoma cell growth 
directly through binding the CXCR4 receptor on tumor 
epithelial cells and augments neoangiogenesis through 
recruiting endothelial progenitor cells (EPCs) [68]. 
Endogenous cyclin D1 also maintained the abundance 
of CCL2, which is known to enhance the retention of 
metastasis-associated macrophages [69].
How might cyclin D1 induce the abundance of 
inflammatory chemokines/cytokines in fibroblasts? 
Cyclin D1 regulates transcription, both in cultured cells 
[70] and in vivo [1, 71], through interacting in the context 
of chromatin with target transcription factors [9, 72] 
recruiting histone regulatory enzymes [70, 73] thereby 
regulating transcription in a kinase-independent manner 
[55]. Herein, cyclin D1 was recuited in the context of 
chromatin to the promoter regulatory regions of several 
cytokine/chemokine genes that were induced by cyclin 
D1, including Csf, Cxcl1, Xcl, and Vcam1 (Supplementary 
Figure 4). Therefore cyclin D1 may induce cytokine/
chemokine expression via this well established 
transcriptional mechanism. 
The mechanisms governing the induction of cyclin 
D1 in the stroma of breast cancer patients is not known. 
Genetic deletion studies have identified components of 
the aberrant signaling pathway in CAFs. In recent studies 
endogenous c-Myc was also shown to participate in the 
development of the inflammatory stromal environment 
[74]. Deletion of the JunD gene in the stroma promoted 
tumor growth and metastasis, associated with increased 
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ROS production, with consequent accumulation of 
HIF1α and HIF1α-dependent induction of CXCL12, 
activating CXCR4, promoting CAF differentiation [75]. 
Hypoxia-induced cancer cells derived TGFβ also drives 
CAF differentiation [68, 76]. Stromal Cav-1 is frequently 
degraded upon hypoxemic induced lysosomal degradation 
and loss of Cav-1 is sufficient to drive the CAF genotype. 
Cav-1 mediates anti-proliferative and survival function via 
the cyclin D1 gene, which is transcriptionally repressed 
by Cav1 [77] via a β-catenin/Tcf pathway [78]. CAF 
gene expression analysis evidence increased expression 
of cell-cycle pathways, increased phosphorylation of 
pRB and loss of Cav1 was highly correlated with poor 
response to tamoxifen therapy [34]. The possibility the 
hypoxia induces degradation of Cav-1 and consequently 
induces cyclin D1 in the breast cancer stroma remains to 
be investigated.
MATERIALS AND METHODS
Gene expression analysis
The abundance of stromal cyclin D1 mRNA in 
breast tumors was determined by Oncomine, a cancer-
profiling database. A cut-off of 1.5-fold enrichment and 
a p-value of <0.05 were used to interrogate the cancer-
profiling database (OncomineTM Research Edition, https://
www.oncomine.org). Comparison of microarray data sets 
representing cyclin D1-dependent and cancer-associated 
fibroblast (CAF) upregulated genes was conducted using 
published data sets [34, 62]. Statistical significance for 
overlapping cyclin D1 induced and CAF-dependent 
genes and Gene Ontology (GO) PANTHER terms were 
calculated using the hypergeometric distance statistical 
formula. The significance level for P values of gene set 
overlap and GO functions was established as P<0.01.
Materials
Antibodies were directed to Ki-67 (AB16667, 
Abcam), calponin (SC136987, Santa Cruz), BECN1 
(sc-11427, Santa Cruz), LC3B (#3868, Cell Signaling), 
LAMP1 (sc-17768, Santa Cruz), F4/80 (ab6640, 
Abcam), CD11b (PA5-18727, Invitrogen), Sca1 
(ab-51317, Abcam), osteopontin (ab8488, Abcam), 
LC3A/B (ab58610, Abcam). Secondary antibodies for 
immunofluorescence were Alexa Green 488 nm and 
Alexa Orange-Red 546 nm (Invitrogen). 4,6-diamidino-
2-phenylindole (DAPI) (D3571), Prolong Gold Anti-fade 
mounting reagent (P36930), Slow-Fade Anti-fade reagent 
(S2828). Osteopontin was obtained from SIGMA (Cat. # 
O2260).
Cell culture
Human skin fibroblasts, immortalized with 
telomerase reverse transcriptase protein (hTERT-BJ-1) 
were originally purchased from Clontech, Inc. and 
transduced with either MSCV-cyclin D1 or MSCV-GFP as 
previously described [8]. The breast cancer cell line MDA-
MB-231 was purchased from ATCC. The hTERT-BJ-1 
and MDA-MB-231 cell lines were obtained in early 2000. 
Mouse embryonic fibroblasts (MEFs) of distinct genotypes 
(cyclin D1-/-, pRB-/-, cyclin D1-/-/pRB-/-) were prepared and 
cultured as previously described [79]. The MEFs of cyclin 
D1-/-, pRB-/-, cyclin D1-/-/pRB-/- and wildtype control were 
generated in 2006 and 2011. All cells were maintained 
in DMEM with 10% Fetal Bovine Serum (FBS) and 
Penicillin 100 units/mL-Streptomycin 100 µg/mL. Mouse 
embryonal stem (ES) cells were cultured following the 
standard protocol [80]. Briefly, tissue culture plates were 
coated with 0.1% (v/v) porcine gelatin (Sigma-Aldrich 
Corp, St. Louis, MO) in Dulbecco’s modified Eagle’s 
medium (DMEM; Invitrogen) in the presence of 15% fetal 
bovine serum (ES-tested Hyclone, Perbio, Logan, UT), 0.1 
mM 2-β-mercaptoethanol, 0.1 mM non-essential amino 
acids, 2 mM glutamine, 0.1 mM sodium pyruvate, and 
1,000 units/ml murine LIF (Chemicon International Inc., 
Temecula, CA). The cell culture medium was changed 
daily. 
The early passage MEFs were stored in liquid 
nitrogen. The cells thawed from low passage stocks were 
used within one month of the initial thaw. During the 
experiments, the morphology of all cell lines was routinely 
checked under phase contrast microscopy. All of the newly 
revived cells were treated with BM-cyclins (Roche) and 
the presence of possible mycoplasma contamination was 
routinely excluded with Hoechst 33258 staining under 
high magnification fluorescent microscope.
Cell co-culture
hTERT-fibroblasts and MDA-MB-231 cells were 
plated on glass coverslips in 12-well plates in 1-ml of 
complete media. MDA-MB-231 cells were plated within 
2 hours of fibroblast plating. The total number of cells per 
well was 1 × 105. Experiments were performed at a 5:1 
fibroblast-to epithelial cell ratio. As controls, monocultures 
of fibroblasts and MDA-MB-231 cells were seeded using 
the same number of cells as the corresponding co-cultures. 
The day after plating, media was changed to DMEM with 
10% NuSerum (a low protein alternative to FBS; BD 
Biosciences) and Penicillin-Streptomycin. Cells were 
maintained at 37°C in a humidified atmosphere containing 
5% CO2. 
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Immunocytochemistry
Immunocytochemistry was performed as 
previously described [81]. All steps were performed at 
room temperature. Briefly, after 30 minutes fixation in 
2% paraformaldehyde, cells were permeabilized for 10 
minutes with immunofluorescence (IF) buffer (PBS, 0.2% 
BSA, 0.1% TritonX-100). Then, cells were incubated for 
10 minutes with NH4Cl in PBS to quench free aldehyde 
groups. Primary antibodies were incubated in IF buffer for 
1 hour. After washing with IF buffer (3x, 10 minutes each), 
cells were incubated for 30 minutes with fluorochrome-
conjugated secondary antibodies diluted in IF buffer. 
Finally, slides were washed with IF buffer (3x, 10 minutes 
each), incubated with the nuclear stain and mounted.
Flow cytometric analysis
GFP+ MDA-MB-231 cells were plated in co-culture 
with hTERT-fibroblasts or in mono-culture. The day 
after, media was changed to DMEM with 10% NuSerum 
and cells were grown for an additional 48 hours. Then, 
to isolate the GFP+ MDA-MB-231 cell population, co-
cultured cells were sorted using a 488 nm laser. As a 
critical control, mono-cultures of GFP+ MDA-MB-231 
cells were sorted in parallel. For DNA content analyses, 
sorted cells were fixed in 70% ethanol overnight at 4°C 
and stained with PI. DNA cell content was analyzed by 
flow cytometry. For proliferation analysis, cells were 
incubated with BrdU (Amersham Pharmacia Biotech) for 
one hour before sorting. Cells were washed in PBS, fixed 
in cold 70% ethanol and flow cytometry was employed for 
analysis of nascent DNA synthesis (BrdU incorporation). 
Cell cycle analysis was performed using FlowJo 8.8 
software. BrdU data was represented as a percentage of 
the total population.
CD34+ hematopoietic stem cell differentiation into 
bone marrow-derived dendritic cells
The effect of stromal cyclin D1-mediated secreted 
factors was tested on the differentiation of CD34+ 
hematopoietic stem cells (HSCs) into bone-marrow 
derived dendritic cells (BMDCs) as described previously 
[82, 83]. Briefly, 30 x 106 BM cells were obtained from 
6- to 10-week-old C57BL/6J mice (purchased from 
The Jackson Laboratory, Bar Harbor, ME) cultured in 
medium obtained from MEF derived from wild type, 
cyclin D1-/- or pRB-/-, or cyclin D1-/-/pRB-/- animals and 
supplemented with 20% of Flt3L, (Fms-related tyrosine 
kinase 3 ligand), containing supernatant, produced 
from an SP2/0 transfected cell line that secretes murine 
recombinant Flt3L [84]. These cells were kindly provided 
by Dr. Robert Rottapel, Ontario Cancer Institute, Toronto 
Medical Discovery Tower, Toronto, Canada. The cells 
were maintained undisturbed at 37°C in 5% CO2 and 90% 
relative humidity. On day 9, the cells were collected by 
gentle trypsinization and phenotyped for marker of stem 
cells (CD34) as well as myeloid (CD11c+/CD11b+/B220-) 
and plasmacytoid (CD11c+/CD11b-/B220+) dendritic cell 
markers, using specific antibodies for flow cytometry as 
described [83]. 
Apoptosis studies
Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) (TACS2 TdT DAB, Trevigen) 
staining was used as a measure of apoptosis in tissues 
as previously described [85]. Apoptosis was quantified 
by Flow Cytometry using the Annexin V-Cy5 apoptosis 
detection kit, as per the manufacturer’s instructions 
(Abcam). 
Western blotting
hTERT-vector and hTERT-cyclin D1 fibroblasts 
were harvested in lysis buffer (10 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1% Triton X-100, 60 mM octylglucoside), 
containing protease inhibitors (Roche Applied Science) 
and phosphatase inhibitors (Roche Applied Science) and 
centrifuged at 13,000x g for 15 min at 4°C to remove 
insoluble debris. After centrifugation to remove insoluble 
debris, protein concentration was determined using the 
Bradford assay (BioRad). 30 µg of proteins were loaded 
and separated by SDS-PAGE and transferred to a 0.2 
µm nitrocellulose membrane (Fisher Scientific). After 
blocking for 30 min in TBST (10 mM Tris-HCl pH 
8.0, 150 mM NaCl, 0.05% Tween-20) with 5% nonfat 
dry milk, membranes were incubated with the primary 
antibody for 1 hour, washed and incubated for 30 min with 
horseradish peroxidase-conjugated secondary antibodies. 
The membranes were washed and incubated with an 
enhanced chemi-luminescence substrate (ECL;Thermo 
Scientific).
Osteopontin ELISA
1.2 x 106 of cells in 2 ml DMEM with 10% FBS 
were seeded in 12-well plate and cultured overnight 
in CO2 incubator at 37oC. The media was then changed 
to FBS-free DMEM media and cultured for another 48 
hours. The culture media was collected and centrifuged 
at 4000 rpm to remove the cell debris. OPN in cultured 
media was measured by Mouse/Rat Osteopontin (OPN) 
Quantikine ELISA Kit from R&D Systems based on the 
manufacture’s protocol. 
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Animal studies
The appropriate Thomas Jefferson University 
institutional committee approved protocols were followed 
when working with all mice. Animals were housed and 
maintained in a pathogen-free environment/barrier facility 
of Thomas Jefferson University under National Institutes 
of Health (NIH) guidelines. Mice were kept on a 12 hours 
light/dark cycle with ad libitum access to chow and water. 
Approval for all animal protocols used for this study was 
reviewed and approved by the Institutional Animal Care 
and Use Committee. The tetracycline inducible mammary 
epithelial cell targeted cyclin D1 transgenic mice (MMTV-
rtTA-cyclin D1WT) and the tamoxifen inducible cyclin D1 
genetic deletion mice (ROSA26-Cre-ERT2-cyclin D1fl/fl) 
were previously described [55].
In brief, transgenic founder lines were backcrossed 
with wild type FVB mouse for three generations to 
obtain the stably inherited transgene line, followed by 
cross mating with MMTV-rtTA line (a kind gift from Dr. 
Lewis Chodosh’s lab) to obtain cyclin D1+/+/rtTA+/+ mice. 
8-week-old tetracycline-inducible cyclin D1/rtTA bi-
transgenic pregnant female mice (12 days postcoitus) were 
administered doxycycline in the drinking water (2 mg/
ml). After 7 days of doxycycline treatment, the mice were 
sacrificed and mammary glands extracted for analysis. 
Conditional cyclin D1fl/fl mice were a generous gift from 
Dr. Sicinski. C57BL/6J ROSA26-Cre-ERT2 mice were a 
kind gift from Dr. Streamson C. Chua Jr. ROSA26-Cre-
ERT2-cyclin D1fl/fl mice were generated by crossing cyclin 
D1fl/fl and ROSA26-Cre-ERT2 mice. Ccnd1 knock-out 
mice were generated by a daily intra-peritoneal injection 
of Tamoxifen (1 mg/200 µl) for 5 days, followed by a 
wash out period of four weeks. Mammary gland tissues 
were then collected. Wild type Cre-ERT2 mice were used 
as control. 
For breast tumor implantation studies, tumor cells 
(MDA-MB-231 (GFP+; 1 × 106 cells) were mixed with 
hTERT-fibroblasts (3 × 105 cells) in 100 µl of sterile PBS 
and were co-injected into the flanks of athymic NCr nude 
mice (NCRNU; Taconic Farms; 6–8 weeks of age). After 
4 weeks, mice were sacrificed; tumors were excised and 
frozen in liquid nitrogen-cooled isopentane.
Survival studies
For statistical analysis, cyclin D1 expression in 
stroma, (high vs low), was derived from data-driven 
optimal cutpoint analysis using X-tile software [36, 86, 
87]. Breast cancer recurrence-free survival was analyzed 
using the Kaplan-Meier survival curve estimator, log-
rank test and Cox proportional hazards model. Nuclear-
localized cyclin D1 levels were compared in normal or 
malignant tissue using t-test.
Paraffin-embedded breast tumor tissues
Breast cancer tissue microarrays were constructed 
from formalin-fixed, paraffin-embedded unselected tumor 
specimens from Thomas Jefferson University Hospital 
pathology archives obtained under IRB approved 
protocols. Patients were diagnosed between the years 1981 
and 2005 with median clinical follow-up data of 8.5 years. 
Quantitative immunofluorescence
Stromal cyclin D1 was detected in clinical 
breast cancer specimens by immunofluorescence-
immunohistochemistry (IF-IHC) performed on an 
Autostainer Plus (Dako) as previously described [87] 
with the following specifications: antigen retrieval used 
the DAKO PT-module with citric acid buffer (pH 6.0) and 
rabbit monoclonal cyclin D1 antibody (Dako, M3635) was 
diluted 1:200 and coincubated with mouse monoclonal 
anti-pancytokeratin (clone AE1/AE3, DAKO, 1:100) for 
45 minutes. 
Quantitative analysis of cyclin D1 was performed 
as previously described [86]{Peck, 2016 #603;Peck, 
2016 #230} using the ScanScope FL line scanner (Leica 
Biosystems) to capture high-resolution digital images 
followed by quantification of cyclin D1 levels in the 
stroma of tumor specimens using Tissue Studio image 
analysis software (Definiens). Briefly, user-guided 
machine learning was performed to generate an analysis 
solution that identified DAPI-stained cell nuclei within the 
stroma of each tumor specimen. Mean nuclear cyclin D1 
signal intensity was calculated for stromal cells in each 
tumor core. 
Cytokine arrays
Human cytokine arrays (ab133997) were obtained 
from Abcam (Cambridge, MA). The medium of hTERT-
controlstroma and hTERT-cyclin D1stroma was prepared 
by culturing cells in DMEM with 10% FBS for 48 hrs. 
Mouse cytokine arrays were purchased from Raybiotech 
(Norcross, GA). Conditioned medium of cyclin 
D1+/+ and cyclin D1−/− MEFs was prepared by culturing 
cells in serum free DMEM for 48 hrs. The experiments 
were conducted exactly as described in the manufacture’s 
protocol.
Proteome analysis of cyclin D1 secretome
Conditioned serum-free media from hTERT-cyclin 
D1 and control hTERT fibroblasts was centrifuged and 
filtered through a 0.22 µm membrane to remove cell 
debris and protease inhibitors were added (1 mM PMSF, 
1 µg/ml leupeptin, and 1 µg/ml pepstatin. Samples were 
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concentrated on 3 KDa MWCO Amicon Ultra-4 centrifugal 
filter units and membranes were washed with 1% SDS, 
10 mM Tris, pH 7.4 to extract adsorbed proteins (70-fold 
final concentration), followed by separation for 0.5 cm on 
10% Bis-Tris NuPAGE gels (Thermo Fisher Scientific). 
In-gel trypsin digestion was performed as described 
previously [88] with the following changes: trypsin was 
used at 4 ng/µl and digests were carried out for 4 hr at 
37 °C. Digested samples were lyophilized, resuspended 
in 0.1% formic acid, 4% acetonitrile immediately prior to 
LC-MS/MS using a Q Exactive Plus mass spectrometer 
(Thermo Fisher Scientific) as previously described [89]. 
Briefly, peptides were separated by reverse-phase using 
a 180 µm x 20 mm nanoACQUITY UPLC Symmetry 
C18 trap column and a 1.7 µm x 250 mm nanoACQUITY 
UPLC Peptide BEH C18 column with 1.7 µm particles 
(Waters) using a 245 min gradient. Data-dependent 
analysis was performed on the 20 most abundant ions 
using an isolation width of 1.5 m/z with a 30 sec dynamic 
exclusion window. Peptide match was preferred, and 
unassigned and single charge ions were rejected. Data 
were analyzed by MaxQuant 1.5.1.2 [90] and the built-
in Andromeda search engine using the UniProt human 
sequence database (July 28, 2014; 145,433 sequences) 
and an in-house database of common contaminants, such 
as keratins, trypsin, and media components (from UniProt, 
July 28, 2014; 3,671 sequences). False discovery rates 
(FDR) for peptides and proteins were set to 1% for the 
initial output. Matching between runs was performed with 
a 0.7 min match window and 20 min alignment window. 
Label-free quantitation (LFQ) was performed with a 
minimum peptide ratio of 1 required for normalization. 
MaxQuant results were processed using Perseus version 
1.5.0.31 [91] and Microsoft Excel 2016. Contaminants 
and protein groups identified by a single peptide were 
removed from the dataset which reduced the protein FDR 
from 1% to 0.5% in the final dataset. LFQ intensities were 
log2 transformed, and missing values were imputted from 
a median downshifted Gaussian distribution with a width 
of 0.3 and downshift of 1.8. Hierarchical clustering was 
performed on Z-scored, log2-transformed LFQ intensities 
using Euclidean distance with k-means preprocessing (300 
clusters). Log2 ratios were calculated as the difference 
in log2 LFQ intensity averages between cyclin D1 and 
control secretomes. Two-tailed, unpaired, homoscedastic 
Student’s t-test calculations were performed for pairwise 
comparisons because the datasets approximated normal 
distributions. Fold-change values for ratios less than 1 are 
represented as negative reciprocals of the ratios. Canonical 
pathway analysis was performed using Ingenuity Pathway 
Analysis (QIAGEN) core analysis. Proteins were mapped 
to Ingenuity Knowledgebase identifiers by gene symbol. 
The entire list of identified proteins was used as the 
reference in statistical calculations.
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